Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus

被引:11
作者
Tschoepe, Diethelm [1 ,2 ]
Bramlage, Peter [3 ]
Schneider, Steffen [4 ]
Gitt, Anselm K. [4 ,5 ]
机构
[1] Stiftung Herzkranke Diabetiker Deutsch Diabetes S, Bad Oeynhausen, Germany
[2] Ruhr Univ Bochum, Fak Med, Herz & Diabeteszentrum Nordrhein Westfalen, Univ Klin, D-32545 Bad Oeynhausen, Germany
[3] Inst Pharmakol & Prevent Med, Mahlow, Germany
[4] Inst Herzinfarktforsch, Ludwigshafen, Germany
[5] Herzzentrum Ludwigshafen, Med Klin B, Kardiol, Ludwigshafen, Germany
关键词
Hypoglycaemia; predictors; glucose variability; comorbidity; adverse effects; GLUCOSE CONTROL; HEART-FAILURE; ANTIDIABETIC PHARMACOTHERAPY; GLYCEMIC VARIABILITY; IMPAIRED AWARENESS; VASCULAR-DISEASE; FOLLOW-UP; FREQUENCY; INSULIN; RISK;
D O I
10.1177/1479164115610470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: With the intensification of antidiabetic treatment, there is an increasing risk of hypoglycaemia. We aimed to determine incidence, characteristics and outcomes. Methods: Prospective, observational, multicenter cohort study. The included 3810 patients with type 2 diabetes had their treatment intensified at baseline. Results: The incidence of hypoglycaemia was 11.4% per year with 4.24.4 episodes per patient. Hypoglycaemia was more frequent in patients with high blood glucose variability. Predictors were heart failure (odds ratio: 1.66; 95% confidence interval: 1.20-2.29) and insulin use (odds ratio: 4.03; 95% confidence interval: 3.05-5.33), with dipeptidyl peptidase-4 inhibitors being associated with reduced risk (odds ratio: 0.69; 95% confidence interval: 0.53-0.89). Macrovascular events were more frequent among patients reporting severe episodes of hypoglycaemia (odds ratio: 3.39; 95% confidence interval: 1.32-8.73). Microvascular events were more frequent in patients with non-severe episodes (odds ratio: 1.92; 95% confidence interval: 1.49-2.49). Conclusion: Case-by-case evaluation of patients as well as appropriate selection of antidiabetic pharmacotherapy and blood glucose treatment goals could maximize the benefits while reducing the risks of antidiabetic treatment.
引用
收藏
页码:2 / 12
页数:11
相关论文
共 43 条
[11]   Hypoglycemia and Cardiovascular Risks [J].
Frier, Brian M. ;
Schernthaner, Guntram ;
Heller, Simon R. .
DIABETES CARE, 2011, 34 :S132-S137
[12]   A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin [J].
Gangji, Azim S. ;
Cukierman, Tali ;
Gerstein, Hertzel C. ;
Goldsmith, Charles H. ;
Clase, Catherine M. .
DIABETES CARE, 2007, 30 (02) :389-394
[13]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[14]  
Gitt AK, 2012, HERZ, V37, P294, DOI 10.1007/s00059-012-3611-3
[15]   Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? [J].
Gitt, Anselm K. ;
Halle, Martin ;
Hanefeld, Markolf ;
Kellerer, Monika ;
Marx, Nikolaus ;
Meier, Juris J. ;
Schumm-Draeger, Petra-Maria ;
Bramlage, Peter ;
Tschoepe, Diethelm .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (12) :1389-1400
[16]   FREQUENCY OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH TYPE-1 DIABETES WITH IMPAIRED AWARENESS OF HYPOGLYCEMIA [J].
GOLD, AE ;
MACLEOD, KM ;
FRIER, BM .
DIABETES CARE, 1994, 17 (07) :697-703
[17]   Impaired awareness of hypoglycaemia: a review [J].
Graveling, A. J. ;
Frier, B. M. .
DIABETES & METABOLISM, 2010, 36 :S64-S74
[18]   Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration [J].
Heller, S. R. ;
Choudhary, P. ;
Davies, C. ;
Emery, C. ;
Campbell, M. J. ;
Freeman, J. ;
Amiel, S. A. ;
Malik, R. ;
Frier, B. M. ;
Allen, K. V. ;
Zammitt, N. N. ;
Macleod, K. ;
Lonnen, K. F. ;
Kerr, D. ;
Richardson, T. ;
Hunter, S. ;
Mclaughlin, D. .
DIABETOLOGIA, 2007, 50 (06) :1140-1147
[19]   Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness [J].
Henderson, JN ;
Allen, KV ;
Deary, IJ ;
Frier, BM .
DIABETIC MEDICINE, 2003, 20 (12) :1016-1021
[20]   A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [J].
Hermansen, Kjeld ;
Davies, Melanie ;
Derezinski, Taudeusz ;
Ravn, Gabrielle Martinez ;
Clauson, Per ;
Home, Philip .
DIABETES CARE, 2006, 29 (06) :1269-1274